Table 2 List of primary antibodies and adequate secondary antibodies to analyze ECM glycoproteins and CSPGs in the retina and optic nerve of control and ischemic eyes via immunohistochemistry.
From: Ischemic injury leads to extracellular matrix alterations in retina and optic nerve
ECM proteins | Primary antibody | Dilution | Reference/source | Secondary antibody | Dilution | Source |
|---|---|---|---|---|---|---|
Glycoproteins | Anti-fibronectin | 1:300 | Goat anti-rabbit Cy3 | 1:300 | Dianova | |
Anti-laminin | 1:300 | Goat anti-rabbit Cy2 | 1:300 | Dianova | ||
Anti-tenascin-C (KAF14 antibody) | 1:250 | Goat anti-rabbit Cy2 | 1:250 | Dianova | ||
Anti-tenascin-R (23–14 antibody) | 1:100 | Goat anti-mouse Cy3 | 1:250 | Dianova | ||
CSPGs | Anti-aggrecan | 1:250 | Merck Millipore | Goat anti-rabbit Cy3 | 1:300 | Dianova |
Anti-brevican | 1:300 | Goat anti-guinea pig Cy2 | 1:300 | Dianova | ||
Anti-phosphacan/ RPTPβ/ζlong (473HD antibody) | 1:200 | Goat anti-rat Cy3 | 1:250 | Dianova | ||
Anti-RPTPβ/ζ-isoforms (KAF13 antibody) | 1:200 | Goat anti-rabbit Cy3 | 1:250 | Dianova |
